

Emanuela Lucci-Cordisco

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5401121/publications.pdf>

Version: 2024-02-01

33
papers

1,399
citations

471509

17
h-index

414414

32
g-index

33
all docs

33
docs citations

33
times ranked

2380
citing authors

#	ARTICLE	IF	CITATIONS
1	The spectrum of WRN mutations in Werner syndrome patients. <i>Human Mutation</i> , 2006, 27, 558-567.	2.5	198
2	A Specific Mutational Signature Associated with DNA 8-Oxoguanine Persistence in MUTYH-defective Colorectal Cancer. <i>EBioMedicine</i> , 2017, 20, 39-49.	6.1	170
3	Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas. <i>Cancer</i> , 2005, 103, 1018-1025.	4.1	136
4	Cancer risk associated with STK11/LKB1 germline mutations in Peutz-Jeghers syndrome patients: Results of an Italian multicenter study. <i>Digestive and Liver Disease</i> , 2013, 45, 606-611.	0.9	113
5	Value of MLH1 and MSH2 Mutations in the Appearance of Muir-Torre Syndrome Phenotype in HNPCC Patients Presenting Sebaceous Gland Tumors or Keratoacanthomas. <i>Journal of Investigative Dermatology</i> , 2006, 126, 2302-2307.	0.7	93
6	Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. <i>Endocrine-Related Cancer</i> , 2012, 19, 149-155.	3.1	71
7	Hereditary nonpolyposis colorectal cancer and related conditions. <i>American Journal of Medical Genetics Part A</i> , 2003, 122A, 325-334.	2.4	70
8	Two PMS2 Mutations in a Turcot Syndrome Family with Small Bowel Cancers. <i>American Journal of Gastroenterology</i> , 2005, 100, 1886-1891.	0.4	65
9	Genetic testing among high-risk individuals in families with hereditary nonpolyposis colorectal cancer. <i>British Journal of Cancer</i> , 2004, 90, 882-887.	6.4	57
10	Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. <i>Cancer Genetics and Cytogenetics</i> , 2006, 166, 124-129.	1.0	48
11	High frequency of mosaic CREBBP deletions in Rubinstein-Taybi syndrome patients and mapping of somatic and germ-line breakpoints. <i>Genomics</i> , 2007, 90, 567-573.	2.9	42
12	BRCA1-Related Malignancies in a Family Presenting with von Recklinghausen's Disease. <i>Gynecologic Oncology</i> , 2002, 86, 375-378.	1.4	39
13	MUTYH-associated polyposis (MAP): evidence for the origin of the common European mutations p.Tyr179Cys and p.Gly396Asp by founder events. <i>European Journal of Human Genetics</i> , 2014, 22, 923-929.	2.8	39
14	The growing complexity of the intestinal polyposis syndromes. <i>American Journal of Medical Genetics, Part A</i> , 2013, 161, 2777-2787.	1.2	37
15	Different molecular mechanisms underlie genomic deletions in the MLH1 Gene. <i>Human Mutation</i> , 2002, 20, 368-374.	2.5	34
16	Mutations of the 'minor' mismatch repair gene MSH6 in typical and atypical hereditary nonpolyposis colorectal cancer. <i>Familial Cancer</i> , 2001, 1, 95-101.	1.9	24
17	Performance of BOADICEA and BRCAPRO genetic models and of empirical criteria based on cancer family history for predicting BRCA mutation carrier probabilities: A retrospective study in a sample of Italian cancer genetics clinics. <i>Breast</i> , 2013, 22, 1130-1135.	2.2	21
18	Double pituitary adenomas. <i>Endocrine</i> , 2013, 43, 452-457.	2.3	18

#	ARTICLE	IF	CITATIONS
19	Four novel MSH2 and MLH1 frameshift mutations and occurrence of a breast cancer phenocopy in hereditary nonpolyposis colorectal cancer. <i>Human Mutation</i> , 2001, 17, 521-521.	2.5	17
20	Frequency of constitutional MSH6 mutations in a consecutive series of families with clinical suspicion of HNPCC. <i>Clinical Genetics</i> , 2007, 72, 230-237.	2.0	16
21	The use of microsatellite instability, immunohistochemistry and other variables in determining the clinical significance of MLH1 and MSH2 unclassified variants in Lynch syndrome. <i>Cancer Biomarkers</i> , 2006, 2, 11-27.	1.7	14
22	A novel microdeletion syndrome with loss of the MSH2 locus and hereditary nonpolyposis colorectal cancer. <i>Clinical Genetics</i> , 2005, 67, 178-182.	2.0	11
23	Genotype-phenotype correlations in individuals with a founder mutation in the MLH1 gene and hereditary non-polyposis colorectal cancer. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 746-753.	1.5	10
24	Universal testing for MSI/MMR status in colorectal and endometrial cancers to identify Lynch syndrome cases: state of the art in Italy and consensus recommendations from the Italian Association for the Study of Familial Gastrointestinal Tumors (A.I.F.E.G.). <i>European Journal of Cancer Prevention</i> , 2022, 31, 44-49.	1.3	9
25	Definition and management of colorectal polyposis not associated with APC/MUTYH germline pathogenic variants: AIFEC consensus statement. <i>Digestive and Liver Disease</i> , 2021, 53, 409-417.	0.9	9
26	Prognostic Relevance of MLH1 and MSH2 Mutations in Hereditary Non-Polyposis Colorectal Cancer Patients. <i>Tumori</i> , 2009, 95, 731-738.	1.1	8
27	The Simpson-Golabi-Behmel syndrome: A clinical case and a detective story. <i>American Journal of Medical Genetics, Part A</i> , 2011, 155, 145-148.	1.2	8
28	Familial microsatellite-stable non-polyposis colorectal cancer: Incidence and characteristics in a clinic-based population. <i>Annals of Oncology</i> , 2001, 12, 813-818.	1.2	7
29	Silent beginning: Early silencing of the MED1/MBD4 gene in colorectal tumorigenesis. <i>Cancer Biology and Therapy</i> , 2009, 8, 192-193.	3.4	6
30	Morphology and Immunophenotyping of a Monolateral Ovary in a 46,XderY/45,X Mosaic Individual With Ambiguous Genitalia. <i>International Journal of Gynecological Pathology</i> , 2010, 29, 33-38.	1.4	4
31	Distribution of Cerebrovascular Phenotypes According to Variants of the ENG and ACVRL1 Genes in Subjects with Hereditary Hemorrhagic Telangiectasia. <i>Journal of Clinical Medicine</i> , 2022, 11, 2685.	2.4	3
32	Three unrelated patients with congenital anterior pituitary aplasia and a characteristic physical and neuropsychological phenotype: A new syndrome?. <i>American Journal of Medical Genetics, Part A</i> , 2012, 158A, 2750-2755.	1.2	2
33	Lynch syndrome with exclusive skin involvement: time to consider a molecular definition?. <i>Familial Cancer</i> , 2019, 18, 421-427.	1.9	0